Menu

Plant Engineered to Produce Higher Levels of Antimalarial Compound

Researchers used the genome sequence of Artemisia annua to boost the plant’s production of artemisinin.

Apr 25, 2018
Catherine Offord

WIKIMEDIA, KRISTIAN PETERSSweet wormwood, Artemisia annua, is the sole source of a potent antimalarial compound called artemisinin. The drug is recommended by the World Health Organization (WHO) as a treatment for malaria caused by Plasmodium falciparum, but supply is currently well below demand.

Now, researchers in China have for the first time published a high-quality genome sequence for A. annua, and genetically modified the plant to produce much higher levels of artemisinin. The results were published yesterday (April 24) in Molecular Plant.

“Nearly half of the world’s population is at risk of malaria,” study coauthor Kexuan Tang of Shanghai Jiao Tong University says in a statement. “Our strategy for the large-scale production of artemisinin will meet the increasing demand for this medicinal compound and help address this global health problem.”

A. annua produces artemisinin at a rate of only about 0.1 percent to 1 percent of the dry weight of its leaves. Alternative approaches to producing the compound have mainly focused on making the drug through other means, for example, via yeast cells engineered to produce a biochemical precursor to artemisinin. But that system is expensive and is not yet ready to replace plant-based production.

In the current study, Tang and his colleagues put together a high-quality draft assembly of the A. annua genome and used it to identify the genetic components of artemisinin biosynthesis. By increasing the expression of three genes involved in this pathway, the team was able to grow plants with much higher levels of artemisinin—up to 3.2 percent of the leaves’ dry weight.

“This is quite an achievement, building as it does on earlier molecular breeding and genetic engineering attempts,” Ian Graham, a biologist at the University of York in the U.K. who was not involved in the work, tells BBC News. However, he says, “before the work could have an impact on commercial production it will require extensive field trials to demonstrate that the engineered plants perform in the field as well as they have done under experimental conditions.”

Graham adds that currently, no genetically modified A. annua have regulatory approval anywhere in the world. “This will be an interesting challenge to gain approval,” he tells BBC News, “particularly in China where the A. annua crop is grown and where the plant is a high profile example of Chinese Traditional Medicine.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.